Pill (Extended Release Capsule) · Lisdexamfetamine dimesylate
Anterosa
Lisdexamfetamine dimesylate in an extended-release capsule (50 to 70 mg). Engineered as a rate-controlled prodrug that converts progressively in red blood cells to deliver steady, smooth monoamine availability across 12 to 14 hours.
- 12-14 h
- Therapeutic arc for continuous deep work.
- 50-70 mg
- Flexible daily titration window.
- Smooth
- Zero mid-afternoon drop-offs or stimulant crashes.
Action & Kinetics
Once absorbed through the digestive tract, Anterosa remains pharmacologically inactive until contact with red blood cells, where enzymatic cleavage slowly strips off the lysine amino acid. This rate-limiting biological conversion produces a consistent, sustained release of active dextroamphetamine that prevents rapid spikes in plasma levels, dampening sudden cardiovascular surges while maintaining executive focus throughout the full working day.
- Active MoleculeLisdexamfetamine dimesylate
- Delivery SystemPill (Extended Release Capsule)
- Nominal Payload50 to 70 mg
- Therapeutic Timing12 to 14 hour operational window
Primary Clinical Effects
- Executive Function RecoveryEliminates morning cognitive latency and hesitation, enabling smooth transition between complex, multi-stage tasks.
- Sustained Task PersistenceLocks in deep analytical concentration that persists through high-friction work sessions without mid-day fatigue.
- Dose-Scaled Cognitive FlowDelivers a predictable, calm working cadence calibrated to personal metabolic titration.
Secondary Reactions & Cautions
The following physiological responses are documented during active administration:
- Resting Pulse & TremorMild adrenergic elevation in resting heart rate and subtle fine motor tremor under heavy workload peaks.
- Metabolic & Appetite BluntingNoticeable reduction in appetite during the active metabolic window; requires structured hydration and scheduled meals.
- Thermoregulation SensitivitySlightly heightened sensitivity to warm ambient conditions and mild daytime diaphoresis.
Administration Protocol: Administer once daily in the early morning with or without food. Avoid afternoon dosing to preserve natural nighttime sleep architecture.
Testing & Sampling Status
Notice: This stuff is real, not fake, and we are currently in the active testing and sampling phase.
All formulations are synthesized and prepared under strict laboratory conditions in Perth, Western Australia. Inquiries for testing dossiers, institutional sampling batches, and analytical specifications should be directed to the engineering team.
Contact hello@caissonai.co or human@caissonai.co for sampling inquiries.